Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + bevacizumab + DC-CIK for advanced colorectal cancer
ChiCTR2000032003Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, bevacizumab and dendritic cell vaccine + cytokine-induced killer cells in colorectal cancer (CRC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective response rate. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
camrelizumabbevacizumabdendritic cell vaccine + cytokine-induced killer cells
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2000032003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032003.